Polaryx Therapeutics (NASDAQ:PLYX) Raised to Hold at Wall Street Zen

Polaryx Therapeutics (NASDAQ:PLYX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

A number of other research firms also recently commented on PLYX. Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Wednesday, July 1st. Zacks Research upgraded shares of Polaryx Therapeutics to a “hold” rating in a research report on Friday, July 10th. Raymond James Financial began coverage on shares of Polaryx Therapeutics in a research report on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price target on the stock. Finally, HC Wainwright initiated coverage on Polaryx Therapeutics in a research report on Thursday, July 9th. They set a “buy” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Polaryx Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Polaryx Therapeutics Price Performance

NASDAQ:PLYX opened at $2.01 on Friday. The business’s 50-day moving average price is $2.18 and its 200 day moving average price is $3.45. Polaryx Therapeutics has a 52-week low of $1.85 and a 52-week high of $48.91. The firm has a market cap of $100.20 million and a P/E ratio of -25.12.

Polaryx Therapeutics (NASDAQ:PLYX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02. Sell-side analysts expect that Polaryx Therapeutics will post -0.22 EPS for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.